CEO: Richard M. Glickman

Sector: Healthcare
Industry:Biotechnology

Exchange: NASDAQ Global Market

Country: USA

Description: Aurinia Pharmaceuticals Inc is a clinical stage pharmaceutical company. The firm is engaged in the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis.


Key numbers

Market Capitalization:714991080
Shares Outstanding: 94326000
Float: 67665605.034
Next Earning Date:2020-03-11
TTm EPS: -0.6886
TTm Dividend Rate:
200 days moving average:6.05
50 days moving average: 5.34
One day percent Change: 78.78



2018-03-31, 2018-06-30, 2018-09-30, 2018-12-31,
2018-03-31, 2018-06-30, 2018-09-30, 2018-12-31,
2015-12-31, 2016-12-31, 2017-12-31, 2018-12-31,
2015-12-31, 2016-12-31, 2017-12-31, 2018-12-31,